Ocugen presents clinical trial data at Eyecelerator conference

Ocugen, Inc.

Presentation furnished as Exhibit 99.1; used at May 2, 2025 Eyecelerator showcase.
Data shows mean change in BCVA and visual field responder proportions.
Specific numerical results not fully extractable due to formatting in filing text.
No new financial results, guidance, or corporate updates provided.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.